Company: MDCXW
Filing Date: 2025-06-30
Form Type: DEF 14A
Source: 0001062993-25-012273
Chunk: 34

Company: Medicus Pharma Ltd.
Filing Date: 2025-06-30
Form: DEF 14A
Chunk 34
---
 disclosed elsewhere in this report, we are not aware of any existing or potential material conflicts of interest between us and any of our directors as of the date hereof. However, certain of our directors are, or may become, directors or officers of other companies with businesses, which may conflict with our business. Accordingly, conflicts of interest may arise which could influence these individuals in evaluating possible acquisitions or in generally acting on our behalf.

Pursuant to the OBCA, our directors are required to act honestly and in good faith with a view to act in our best interests. Generally, as a matter of practice, directors who have disclosed a material interest in any contract or transaction that the Board is considering will not take part in any board discussion respecting that contract or transaction. If on occasion such directors do participate in the discussions, they will refrain from voting on any matters relating to matters in which they have disclosed a material interest. In appropriate cases, we will establish a special committee of independent directors to review a matter in which directors or officers may have a conflict.

<div align='center'>- 28 -</div>

THE BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE "" THE ELECTION OF THE NOMINEES IN PROPOSAL 2.

<div align='center'>PROPOSAL 3 - QUORUM AMENDMENT</div>

The Company ceased to be a foreign private issuer under U.S. securities laws as of January 1, 2025. The corporate governance rules of Nasdaq (the "Nasdaq Rules") require the Company, having ceased to be a foreign private issuer, to have a quorum requirement for the transaction of business at a meeting of Shareholders of not less than 33⅓% of the outstanding shares of a Company's common voting stock.

On May 6, 2025, the Board approved an amendment to Article 3.2 of the Company's by-laws to replace the reference to "10%" with a reference to "33⅓%" (the "Quorum Amendment") to comply with the Nasdaq Rules.

After giving effect to the Quorum Amendment, the full text of Section 3.2 of the Company's by-laws is as follows:

3.2 Quorum at Meetings of Shareholders

A quorum for the transaction of business at any meeting of shareholders shall be 2 voting persons holding or representing in the aggregate not less than 33⅓% of the issued and outstanding shares of the Company, or of the class